Axogen competitors

Terry Rich works at NUVASIVE INC and a President/CEO at RTI SURGICAL, INC. and Board Member at RTI SURGICAL, INC.. He has worked as Board Member at ALPHATEC HOLDINGS, INC.; Senior VP:Sales at NUVASIVE INC; and President/COO at ALPHATEC HOLDINGS, INC.. Terry attended Rutgers University.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.

John Ducker is a Plant Manager at Fresenius SE Group, President/CEO at Fresenius Kabi USA, and Director at FRANCESCA'S HOLDINGS CORP. He has worked as Board Member at FRESENIUS KABI ONCOLOGY LIMITED, President/CEO at App Pharmaceuticals Inc., and Board Member at Dabur Pharma Co. Ltd. John studied at University of Cambridge.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® - coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.